How does the serum format differ from injectable GHK-Cu
The MHRA has forcefully intervened, explicitly stating that any clinic or digital vendor making medicinal claims regarding these peptidessuch as claiming BPC-157 aids in tissue repair or GHK-Cu reverses agingis in direct, flagrant breach of the Human Medicines Regulations 2012
The second theory is that addictive substances change the brains circuits, making them hypersensitive
Regulation and boundary between cosmetic, medical device and medicine In Europe, topical peptides fall under three distinct regulatory frameworks according to their claim and mechanism: Cosmetic (EC Regulation 1223/2009) Surface cutaneous action, beauty and hygiene claims No therapeutic claim authorised Product information file (PIF), safety evaluation Examples: Matrixyl, Argireline, Pal-GHK in anti-ageing serums Medical device (EU Regulation 2017/745) Main physical/mechanical action, medical claim Classes I, IIa, IIb, III according to risk CE marking mandatory, notified bodies for class IIa+ Example: GHK-Cu dressings for wound healing Medicine (Directive 2001/83/EC) Explicit therapeutic claim, pharmacological action MA mandatory (EMA or national agencies), phase I-III clinical trials Example: Afamelanotide for erythropoietic protoporphyria (MA 2014) This segmentation has direct implications for research : a molecule can change regulatory status according to its final formulation and claims
